Trimethobenzamide
Tigan, Trimethobenzamide (trimethobenzamide) is a small molecule pharmaceutical. Trimethobenzamide was first approved as Tigan on 1982-01-01. It is used to treat nausea and vomiting in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
Tigan, Trimethobenzamide (discontinued: Tigan, Trimethobenzamide)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| tigan | New Drug Application | 2024-10-16 |
| tigan(r) (trimethobenzamide hydrochloride) | New Drug Application | 2024-01-28 |
| trimethobenzamide | ANDA | 2023-01-12 |
| trimethobenzamide hydrochloride | ANDA | 2024-04-04 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| vomiting | HP_0002013 | D014839 | R11.1 |
| nausea | HP_0002018 | D009325 | R11.0 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J3250 | Injection, trimethobenzamide hcl, up to 200 mg |
| Q0173 | Trimethobenzamide hydrochloride, 250 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
Clinical
Clinical Trials
8 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Parkinson disease | D010300 | EFO_0002508 | G20 | 1 | — | — | 2 | — | 3 |
| Infertility | D007246 | HP_0000789 | — | — | — | — | 1 | — | 1 |
| Motor disorders | D000068079 | — | — | — | — | — | 1 | — | 1 |
| Vomiting | D014839 | HP_0002013 | R11.1 | — | — | — | 1 | — | 1 |
| Nausea | D009325 | HP_0002018 | R11.0 | — | — | — | 1 | — | 1 |
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hyperkinesis | D006948 | HP_0000752 | — | — | — | — | — | 1 | 1 |
| Attention deficit disorder with hyperactivity | D001289 | EFO_0003888 | F90 | — | — | — | — | 1 | 1 |
| Myopia | D009216 | EFO_0003927 | H52.1 | — | — | — | — | 1 | 1 |
| Refractive errors | D012030 | EFO_0003908 | H52.7 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Trimethobenzamide |
| INN | trimethobenzamide |
| Description | Trimethobenzamide is the amide obtained by formal condensation of 3,4,5-trihydroxybenzoic acid with 4-[2-(N,N-dimethylamino)ethoxy]benzylamine. It is used to prevent nausea and vomitting in humans. It has a role as an antiemetic. It is a tertiary amino compound and a member of benzamides. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COc1cc(C(=O)NCc2ccc(OCCN(C)C)cc2)cc(OC)c1OC |
Identifiers
| PDB | — |
| CAS-ID | 138-56-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201256 |
| ChEBI ID | 27796 |
| PubChem CID | 5577 |
| DrugBank | DB00662 |
| UNII ID | W2X096QY97 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Trimethobenzamide
+
Benzocaine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Trimethobenzamide
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 306 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
235 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use